Global Ganja Report

There has been mounting speculation in recent months that Jamaica is really about to finally decriminalize ganja (as it is ubiquitously called there, even in official circles). But now there has been something approaching official confirmation. A March 6 report on MercoPress news service cites a statement from Dealana Seiveright, leader of the Caribbean nation's Cannabis Commercial and Medicinal Research Taskforce (CCMRT), in turn quoting a statement from Science, Technology, Energy and Mining Minister Phillip Paulwell, who assured that "ganja will be decriminalized in Jamaica this year and emphasized that Jamaica cannot be allowed to be left behind on the issue."  Seiveright added: "He also reiterated the multiple economic, social and cultural benefits that Jamaica stands to gain if the laws are adjusted sooner rather than later."

Lawmakers from Mexico's left-wing Party of the Democratic Revolution (PRD) introduced legislation last week to decriminalize cannabis in an effort to curb cartel violence. One bill, introduced in the federal Congress, builds on the partial decrim passed in 2009, increasing "personal use" quantities from five to 30 grams. It also includes provisions allowing for use of medical marijuana. Another bill in the Federal District's Legislative Assembly would instruct police and judges in Mexico City to deprioritize prosecution of cannabis violations. It would also create "tolerance zones," where cannabis could be sold openly, and "dissuasion commissions" to which violators could be assigned in lieu of criminal charges.

Medical marijuana advocates are applauding a new memorandum (PDF) issued Feb. 14 by the US departments of Treasury and Justice giving long-awaited guidance to financial institutions to provide services to cannabis-related businesses in states where such commerce is legal. The memo "clarifies customer due diligence expectations and reporting requirements for financial institutions seeking to provide services to marijuana businesses," said a press release issued by the Treasury Department's Financial Crimes Enforcement Network (FinCEN). The memo also includes clarity for credit card service companies, such as VISA and MasterCard, whose services for cannabis-related businesses had also been suspended for years.

Eighteen members of Congress joined together Feb. 12 in calling on President Barack Obama to use his authority to reclassify cannabis from its current position as a dangerous drug with no medical value, alongside heroin and LSD. The letter (PDF) says that cannabis' current status "makes no sense," and requests that Obama "instruct Attorney General Holder to delist or classify marijuana in a more appropriate way." The Congressional letter comes just days after Obama told The New Yorker magazine that marijuana was less dangerous than alcohol.

Uruguay is still developing its nascent cannabis economy following the Christmas Eve signing of the new legalization law, but its leaders have already broached international exports. Diego Cánepa, media spokesman for President José Mujica, said that while development of the domestic market is the priority, representatives from countries including Israel, Canada and Chile have contacted Uruguay to inquire on importing prospects.  "It was not the law’s intention to regulate international trade of marijuana, but Uruguay is open and enthusiastic at the possibility," said Cánepa to Montevideo newspaper La Red 21 in comments picked up by International Business Times. Several private companies have even expressed interest in opening cannabis laboratories in Uruguay, he said. "It would be a challenge, if labs were to open installations in Uruguay," admitted Cánepa. "It goes beyond what the law previewed, but it would turn Uruguay into a biotechnology center. That is a huge step forward."

Medical marijuana advocates are telling President Barack Obama he has the power to reclassify cannabis after he said Jan. 31 it is up to Congress. In an exclusive CNN interview, Obama responded to a question about the federal cannabis classification by saying that, "what is and isn't a Schedule I narcotic is a job for Congress." Responded Steph Sherer, executive director of Americans for Safe Access (ASA): "President Obama just told the nation during his State of the Union address that because Congress has been unable to act, he would take executive action where he could on behalf of helping the American people,. The president has the authority to reclassify marijuana and could exercise that authority at any time."

New York Governor Andrew Cuomo announced during his State of the State address on Jan. 8 plans for a medical marijuana pilot program that would permit up to 20 hospitals to distribute cannabis to patients with serious illnesses. According to a press release, the pilot program "will allow qualified eligible participants to seek relief for their symptoms in a safe and legal manner, while also evaluating the effectiveness and feasibility of a medical marijuana system," with the findings of the program to help shape future policy. The plan creates the program within current New York statutory authority—specifically, the Controlled Substances Therapeutic Research Act of 1980, which allows the state to establish medical marijuana research programs in hospitals. Critics have claimed that the reliance on this statute is unworkable in the long-term. (Jurist, Jan. 9)

In an historic move, the American Herbal Pharmacopoeia (AHP) released the first installation of a two-part Cannabis Monograph (PDF) Dec. 10 that classifies marijuana as a botanical medicine, alongside many other widely accepted "Complementary and Alternative Medicines." Written and reviewed by leading experts, the monograph brings together an authoritative compendium of scientific data, including long-awaited standards for the plant's identity, purity, quality and properties. The monograph provides a foundation for health care professionals to integrate cannabis therapy into their practices on the basis of a full scientific understanding of the plant, its constituent components, and its biologic effects.